spacer
home > ict > spring 2018 > revolution or evolution?
PUBLICATIONS
International Clinical Trials

Revolution or Evolution?

The pharmaceutical industry is abuzz with visions of cloudenabled services and new technologies that foretell a digital transformation of the clinical trial process. Recent industry conferences have focused on the ‘virtualisation’ of trials, forecasting patient-direct, ‘visit-/site-less’ approaches underpinned by strides in artificial intelligence (AI). In this worldview, a new generation of healthcare-grade wearable devices will feed a shareable, platform-agnostic ‘Big Data’ machine that revolutionises the world of drug development – or so many pundits say.

The vision of the future and the promise of speed and efficiency for drug development is exciting and aweinspiring. However, the reality of Big Data, automation, and AI accelerating drug discovery will – and should – come as an evolution in clinical trials, not a revolution.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
David Goldston is Managing Director at Veracity Logic – an IRT company based in North Carolina that deployed IRT systems for clinical trials in more than 50 countries over the past decade. He has more than 25 years of experience in the healthcare and clinical research industries, including clinical data management for Quintiles and PPD. David also served as Computer Systems Administrator for the office of information systems at the University of North Carolina at Chapel Hill School of Medicine, US. He earned a master’s degree in information science at the University of North Carolina at Chapel Hill, US.
spacer
David Goldston
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Novo Nordisk Pharmatech A/S enters a distribution agreement with Signet Chemical Corporation Pvt. Ltd. for cGMP Quaternary Ammonium Compounds for pharmaceutical and medical device applications

Novo Nordisk Pharmatech A/S has entered into an agreement with Signet Chemical Corporation Pvt. Ltd. for the distribution of their pharmaceutical range of quaternary ammonium compounds (FEF® Quats) to the healthcare industry in India, Bangladesh and Sri Lanka.
More info >>

White Papers

Value-Added Processing and Quality By Design Principles Help Meet High-Quality Demands

West Pharmaceutical Services, Inc.

The current pharmaceutical market has faced a variety of challenges, including increasing expectations for quality from end-users and regulatory agencies driven by concern for patient safety. While pharmaceutical companies are working to assure that new quality and compliance paradigms are met, a balance must be achieved between the reality of managing costs in an effort to provide a product that meets the requirements of payers along with facilitating profitability in order to continue adequate business reinvestment.
More info >>

 
Industry Events

6th Annual Single Cell Analysis Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its 6th Annual Single Cell Analysis Congress taking place on 8-9 November 2018 in London.  Part of the Genomics & Synthetic Biology Series UK, the congress will bring together over 600 end users representing internationally renowned research & academic institutions, clinical research institutions, healthcare organisations as well as leading pharmaceutical and biotech companies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement